Taken together, our data suggest that CCR6+CCR2+ cells are type 17 cells with a pathogenic signature that, although resting in the blood, can enter the CNS and, in patients with MS, show increases in markers of pathogenicity and activation that suggest the potential to contribute to disease-associated inflammation. Here, CCR6 is linked to myeloid sarcoma.